Neurol. praxi. 2008;9(3):160-164

Hypnotika v léčbě nespavosti

MUDr. Martin Pretl, CSc.
Neurologická klinika 1. LF UK a VFN, Praha

V léčbě nespavosti hraje důležitou roli jak druh insomnie, tak typ pacienta. Hypnotika mají své nezastupitelné místo v léčbě akutní nespavosti. Chronická insomnie patří do rukou specialisty. V léčbě je doporučována psychoterapie KBT a agonisté benzodiazepinových receptorů.

Keywords: hypnotika, nespavost, benzodiazepinový receptor, agonisté benzodiazepinových receptorů

Published: July 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pretl M. Hypnotika v léčbě nespavosti. Neurol. praxi. 2008;9(3):160-164.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Blin O, Micallef-Rolle J, Legangneux E and Zobouyan F. Zolpidem modified-release 12.5 mg has no residual effects on psychomotor performance and cognitive function in healthy adult subjects. Sleep 2005; 28: A246.
    2. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60: 413-445. Go to original source... Go to PubMed...
    3. Ebert B, Wafford KA, Deacon S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther 2006; 112: 612-629. Go to original source... Go to PubMed...
    4. Hajak G. New paradigms in the pharmacological treatment of insomnia. Sleep Medicine 2006; 7(S1): S20-S26. Go to original source...
    5. Hindmarch I, Patat A, Stanley N, Paty I, Rigney U. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening, Hum Psychopharmacol 2001; 16: 159-167. Go to original source... Go to PubMed...
    6. Hindmarch I, Stanley N, Legangneux E, Embego S. Zolpidem modified-release significantly reduces latency to persistent sleep 4 and 5 hours post dose compared with standard zolpidem in a model assessing the return to sleep following nocturnal awakening. Sleep 2005; 28: A245-A246.
    7. Iber C, Ancoli-Israel S, Chesson A Quan SF for the American Academy of sleep Medicine. The AASM Manual for the Scoring of Sleep and Associate Events: Rules, terminology and technical Specifications. 1st ed: Westchester, Illinois: American Academy of Sleep Medicine, 2007.
    8. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebocontrolled study in adults with chronic insomnia. Sleep 2003; 26: 793-799. Go to original source... Go to PubMed...
    9. Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci 2004; 27: 569-575. Go to original source... Go to PubMed...
    10. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology, J Pharmacol Exp Ther 2002; 300: 2-8. Go to original source... Go to PubMed...
    11. NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. 2005; 22(2): 1-30.
    12. Ohayon MM. Prevalence and correlates of nonrestorative sleep complaints. Arch Intern Med. 2005; 165: 35-41. Go to original source... Go to PubMed...
    13. Pretl M, Praktický lékař a nespavost, Med. Pro Praxi 2008; 5(3): 123-126.
    14. Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002; 471: 103-110. Go to original source... Go to PubMed...
    15. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999; 14: 287-303. Go to original source... Go to PubMed...
    16. Subramanian S, Surani S. Sleep disorders in the elderly. Geriatrics. 2007; 62: 10-32. Go to PubMed...
    17. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia, Sleep Med 2005; 6: 487-495. Go to original source... Go to PubMed...
    18. Wade A, Zisapel N, Lemoine P. Prolonged-release melatonin for the treatment of insomnia: targeting quality of sleep and morning alertness. Aging Health 2008; 4: 11-21. Go to original source...
    19. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000; 4: 551-581. Go to original source... Go to PubMed...
    20. World Health Organization Expert Committee on Drug Dependence. Thirty-third report, World Health Organ Tech Rep Ser. 2003; 915: 1-26.
    21. Zhdanova IV. Advances in the management of insomnia. Expert Opin Pharmacother 2004; 5: 1573-1579. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.